 22. The participant has active liver disease or jaundice, or with alanine aminotransferase ALT, aspartate aminotransferase AST, or bilirubin total bilirubin 1.5 times the upper limit of normal ULN in the clinical laboratory tests at VISIT 1 and 2. 